argenx与Forte Biosciences达成22亿美元交易

2026-07-27 16:20

argenx SE (ARGX) to acquire Forte Biosciences (FBRX) for $77 per share in cash, valuing the transaction at ~$2.2B.
The acquisition will add Forte’s lead program, FB102, a first-in-class anti-CD122 antibody, to argenx’s (ARGX) immunology portfolio.
Under the agreement, argenx (ARGX) will launch a cash tender offer for all outstanding Forte shares at $77 per share, representing an ~86% premium to Forte’s volume-weighted average price since the company reported positive Phase 1b vitiligo data on July 9, 2026.
The transaction is expected to close in Q3 2026.
"The addition of FB102 to our portfolio aligns perfectly with the argenx playbook: compelling biology, strong clinical validation and broad potential to address patient need. I am grateful to the Forte Biosciences team for their outstanding work. Together, we look forward to unlocking the full potential of FB102 and accelerating its impact for patients.” said said Karen Massey, CEO, argenx.
FBRX (FBRX) stock price jumped about 39% on Monday during pre-market hours of trading, while ARGX (ARGX) traded 6% lower.

More on argenx SE, Forte Biosciences